The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) to set a negotiated price for

Even after Trump’s new deal, obesity drugs are still too expensive.

The Trump administration’s new TrumpRx deal with Eli Lilly and Novo Nordisk will slash GLP-1 drug prices, including Ozempic, Wegovy, and Zepbound, to as low as $245 per dose for Medicare, Medicaid, and direct consumers.